about
KASL clinical practice guidelines: management of chronic hepatitis BBlood Lead Levels and Cause-Specific Mortality of Inorganic Lead-Exposed Workers in South KoreaHBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea.Quantitative measurement of serum hepatitis B surface antigen using an immunoradiometric assay in chronic hepatitis BHepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohortFactors associated with alcohol consumption in hepatitis B carriers: a nationwide study in the Republic of Korea.Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy.Determinants of suboptimal hepatitis B vaccine uptake among men in the Republic of Korea: where should our efforts be focused: results from cross-sectional study.Hepatitis B virus-related glomerulonephritis: not a predominant cause of proteinuria in korean patients with chronic hepatitis B.Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patientsInfectious diseases in children and adolescents in the Republic of Korea; Past & recent statusEfficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study.Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea.Clinical features of acute viral hepatitis B in Korea: a multi-center study.Hepatitis B: Epidemiology and prevention in developing countries.The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea: a multi-center, nation-wide, cross-sectional epidemiologic study.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Prevalence of and factors influencing impaired glucose tolerance among hepatitis B carriers: a nationwide cross-sectional study in the Republic of Korea.Ten-Year Changes in the Hepatitis B Prevalence in the Birth Cohorts in Korea: Results From Nationally Representative Cross-Sectional SurveysFighting Hepatitis B in North Korea: Feasibility of a Bi-modal Prevention Strategy.Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels.Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failuresIron deficient erythropoiesis might play key role in development of anemia in cancer patients.Recent trends in hepatitis B virus infection in the general Korean populationLamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patientsThen and now: the progress in hepatitis B treatment over the past 20 years.The management of chronic hepatitis B in Asian Americans.Serum selenium levels in Korean hepatoma patients.Work-related infectious diseases among Korean workers compensated under the Industrial Accident Compensation Insurance Law, 2006-2011.A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy.Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.Nationwide seroepidemiology of hepatitis B virus infection in South Korea in 2009 emphasizes the coexistence of HBsAg and anti-HBs.Association of Hepatitis B Virus Infection and Psoriasis.Baracle® vs Baraclude® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety.Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B.Cost-effectiveness of antiviral prophylaxis during pregnancy for the prevention of perinatal hepatitis B infection in South Korea.
P2860
Q26752475-40301DAC-AA5D-4695-931F-853D4B268CFFQ28391274-9B86DFA2-3583-4BF2-999D-CC213B8E1A9AQ30741676-A934BFC2-0F52-409D-A4EC-7E814D4CFEECQ30829485-637CD111-0419-4E6E-B7DA-3E2C2160C013Q31101980-B137988B-1A2D-40BF-AF90-F9615AA2969FQ33704165-25F7B07B-A2AE-4968-9D59-ADB2593CFC2CQ34339613-FE229575-3B59-49C9-896C-92DE7101B6C6Q34459368-F428E993-9113-4398-BA04-BB9BA62F250DQ34489138-AE49C039-B11B-4AFE-94D8-18831AD85CBCQ34627978-817D8437-1765-4A5B-9570-08DC7A143D1BQ34721811-478E409B-5DD4-486B-B07A-A16F0FE05600Q35144067-DFE99D05-ED56-43CE-AC46-EC737D7A02BBQ35681979-6020FAA7-2BAD-4B5C-9DA0-42621C8804A1Q35742858-447B8FC5-20BC-4BB2-B242-930A41862D6CQ35778355-89DC903F-309B-4D97-A38F-F750AD2ED028Q35833042-E901212E-6FD1-4B5A-A682-239CF3B2C4D5Q35833240-A3CC62C7-4B6A-4522-9615-AF736FF63E34Q35875838-650FC4D9-2475-4B5B-ADDF-652D569C4AC2Q35931235-BCB0E653-8B95-4B40-98DD-A11BDFFD7814Q36153966-751E3B70-3B38-4659-9F8E-5D253317ACB9Q36193481-ADFB043A-DC14-49A0-808E-536584693087Q36195572-577720F8-C089-48A4-8A38-EABBCB5F4547Q36241702-AC1EB2DA-A141-469F-BD55-2DFC846AF22AQ36241726-1A22B409-6652-4531-B692-6BDCA02E4313Q36492640-CC423667-08A7-4444-BBE1-1AA232C937ACQ36619022-42BE4539-3A63-4124-8C36-04BAE0740FC5Q37015281-0CC083D4-3B3F-464F-AA96-1CBDCF79F24EQ37229870-14BA645E-86C9-4912-975D-DA1333D5C569Q37581346-82C9355B-2AAD-4401-9A43-5555B62C42CCQ37936321-D253CD2D-A88B-4B31-B2D6-0788B2254E31Q37983529-404955A4-3F0C-4FB0-8CC2-8262A97A83C5Q38421988-3F736096-5D2E-4328-A6D7-D4172BA958FBQ40318439-51E8F4A4-2BCE-4A1C-B547-289BCFC639FFQ41465525-5DDF65C8-3B82-47A4-9693-5C53ED69CCD8Q41930574-DAF94F1E-E0AD-490F-B993-CB42DED3EAF9Q44905340-0FF30666-266A-49FB-8706-F8DE328FE6D5Q45323858-3378A4DA-DA96-4305-B6B4-5761399539B0Q47151413-9A9DB3BA-1F06-439D-9B7C-39EC4FCD737AQ47195767-38F6979D-52E6-4CA5-A48D-848B47E9E12EQ50235126-60545A62-219C-45EF-A854-14B1A2A6F712
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status of liver diseases in Korea: hepatitis B.
@en
Current status of liver diseases in Korea: hepatitis B.
@nl
type
label
Current status of liver diseases in Korea: hepatitis B.
@en
Current status of liver diseases in Korea: hepatitis B.
@nl
prefLabel
Current status of liver diseases in Korea: hepatitis B.
@en
Current status of liver diseases in Korea: hepatitis B.
@nl
P2093
P1476
Current status of liver diseases in Korea: hepatitis B.
@en
P2093
Hee Bok Chae
Hyung Joon Yim
Ja Kyung Kim
Jong-Hyun Kim
P304
P356
10.3350/KJHEP.2009.15.S6.S13
P478
15 Suppl 6
P577
2009-12-01T00:00:00Z